We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
26
PUT
iShares Russell 2000 ETF
IWM
$80.8B
$18.8M 0.86%
62,500
+35,000
+127% +$9.84M
SPY icon
27
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$18.7M 0.85%
+25,000
New +$18.1M
NKTR icon
28
Nektar Therapeutics
NKTR
$2.48B
$17M 0.78%
244,184
+82,932
+51% +$6.07M
INSP icon
29
Inspire Medical Systems
INSP
$1.78B
$16.7M 0.76%
374,617
-30,580
-8% -$1.45M
RVMD icon
30
Revolution Medicines
RVMD
$44.6B
$16.4M 0.75%
87,509
-46,384
-35% -$6.78M
ESTA icon
31
Establishment Labs
ESTA
$2.11B
$15.9M 0.73%
185,619
-27,854
-13% -$2M
PRTA icon
32
Prothena Corp
PRTA
$479M
$15.2M 0.7%
1,554,535
-26,908
-2% -$266K
RYTM icon
33
Rhythm Pharmaceuticals
RYTM
$7.38B
$15.1M 0.69%
136,158
-75,292
-36% -$6.81M
IKT icon
34
Inhibikase Therapeutics
IKT
$336M
$15M 0.69%
7,387,205
+780,633
+12% +$1.4M
QURE icon
35
uniQure
QURE
$3.38B
$15M 0.68%
324,672
+248,466
+326% +$6.5M
RLYB icon
36
Rallybio
RLYB
$89.3M
$14.8M 0.68%
926,352
+905,817
+4,411% +$11.7M
REGN icon
37
Regeneron Pharmaceuticals
REGN
$81.8B
$13.8M 0.63%
22,208
+10,054
+83% +$6.84M
IVA
38
Inventiva
IVA
$1.11B
$13.6M 0.62%
3,606,656
+1,432,258
+66% +$6.88M
STRO icon
39
Sutro Biopharma
STRO
$339M
$13.4M 0.61%
404,014
-120,427
-23% -$3.75M
IONS icon
40
Ionis Pharmaceuticals
IONS
$10.1B
$13.2M 0.6%
166,286
+5,948
+4% +$448K
BBIO icon
41
BridgeBio Pharma
BBIO
$15B
$13.2M 0.6%
176,689
+82,397
+87% +$5.77M
SRPT icon
42
Sarepta Therapeutics
SRPT
$2.2B
$13.1M 0.6%
730,649
+468,591
+179% +$8.86M
CTMX icon
43
CytomX Therapeutics
CTMX
$699M
$12.6M 0.58%
3,365,118
-45,072
-1% -$172K
VOR icon
44
Vor Biopharma
VOR
$1.34B
$12.5M 0.57%
+680,626
New +$10.3M
BIL icon
45
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
$12.4M 0.57%
135,585
– –
EQ icon
46
Equillium
EQ
$152M
$12M 0.55%
3,758,569
+31,910
+0.9% +$76.5K
ANL
47
Adlai Nortye Group ADS
ANL
$890M
$11.7M 0.54%
1,017,805
+899,896
+763% +$11M
CLYM
48
Climb Bio
CLYM
$837M
$10.7M 0.49%
822,649
+224,987
+38% +$2.32M
XBI icon
49
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$10.7M 0.49%
67,400
+52,400
+349% +$7.08M
HLXC
50
Helix Acquisition Corp III
HLXC
$238M
$10.6M 0.49%
1,000,000
– –
1
2
3 4 5

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.